Fiche publication
Date publication
septembre 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry
,
Dr LAMBERT Aurélien
Tous les auteurs :
Lambert A, Schwarz L, Ducreux M, Conroy T
Lien Pubmed
Résumé
Complete surgical resection is the cornerstone of curative therapy for resectable pancreatic adenocarcinoma. Upfront surgery is the gold standard, but it is rarely curative. Neoadjuvant treatment is a logical option, as it may overcome some of the limitations of adjuvant therapy and has already shown some encouraging results. The main concern regarding neoadjuvant therapy is the risk of disease progression during chemotherapy, meaning the opportunity to undergo the intended curative surgery is missed. We reviewed all recent literature in the following areas: major surveys, retrospective studies, meta-analyses, and randomized trials. We then selected the ongoing trials that we believe are of interest in this field and report here the results of a comprehensive review of the literature. Meta-analyses and randomized trials suggest that neoadjuvant treatment has a positive effect. However, no study to date can be considered practice changing. We considered design, endpoints, inclusion criteria and results of available randomized trials. Neoadjuvant treatment appears to be at least a feasible strategy for patients with resectable pancreatic cancer.
Mots clés
FOLFIRINOX, chemoradiotherapy, gemcitabine, nab-paclitaxel, neoadjuvant chemotherapy, pancreatic cancer, surgery
Référence
Cancers (Basel). 2021 Sep 21;13(18):
